TLR9 and melanoma: Tilsotolimod, a CpG‐C TLR9 agonist, appeared to have promising clinical activity when combined with ipilimumab in early‐phase studies27; however, no RECIST v1.1 responses were observed with tilsotolimod monotherapy (n = 54, including 16 patients with melanoma).28